{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nekvindova L"],"funding":["Ministerstvo Zdravotnictví Ceské Republiky"],"pagination":["11"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7789592"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["<h4>Background</h4>Treat-to-target (T2T) is a widely accepted strategy for patients with rheumatoid arthritis (RA). It recommends attaining a goal of at least low disease activity (LDA) within 6 months; otherwise, the current therapy should be modified. We aimed to investigate whether switching a first-line targeted therapy (TT) in patients not reaching LDA within 6 months leads to a higher probability of meeting LDA at the 12-month visit in daily clinical practice using data from Czech registry ATTRA.<h4>Methods</h4>We included patients with RA starting the first-line TT from 1 January 2012 to 31 January 2017 with at least 1-year follow-up. We created four mutually exclusive cohorts based on (1) switching to another TT within the first year and (2) reaching a treatment target (DAS28-ESR ≤"],"journal":["Arthritis research & therapy"],"pubmed_title":["Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry."],"pmcid":["PMC7789592"],"funding_grant_id":["00023728"],"pubmed_authors":["Nekvindova L","Vencovsky J","Kristkova Z","Horak P","Pavelka K","Zavada J"],"additional_accession":[]},"is_claimable":false,"name":"Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry.","description":"<h4>Background</h4>Treat-to-target (T2T) is a widely accepted strategy for patients with rheumatoid arthritis (RA). It recommends attaining a goal of at least low disease activity (LDA) within 6 months; otherwise, the current therapy should be modified. We aimed to investigate whether switching a first-line targeted therapy (TT) in patients not reaching LDA within 6 months leads to a higher probability of meeting LDA at the 12-month visit in daily clinical practice using data from Czech registry ATTRA.<h4>Methods</h4>We included patients with RA starting the first-line TT from 1 January 2012 to 31 January 2017 with at least 1-year follow-up. We created four mutually exclusive cohorts based on (1) switching to another TT within the first year and (2) reaching a treatment target (DAS28-ESR ≤","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-05-29T19:36:30.492Z","creation":"2025-05-29T19:36:30.492Z"},"accession":"S-EPMC7789592","cross_references":{"pubmed":["33407803"],"doi":["10.1186/s13075-020-02393-8"]}}